Back to results
US 2006/0052390 A1Published application
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
AssigneeScios, Inc.
InventorsGeorge Schreiner, Andrew Protter, Linda Higgins
Life of this patent
Estimating the term…
Abstract
The present invention provides a method to treat multiple myeloma by the co-administration of one or more p38 MAP kinase inhibitors with one or more proteosome inhibitors.
Claims20
A method to treat multiple myeloma in a subject, comprising:
- co-administering to a subject in need of such treatment a therapeutically effective amount of a p38 inhibitor and a therapeutically effective amount of a proteasome inhibitor, whereby a symptom associated with multiple myeloma is ameliorated.
A method of inhibiting cytokine secretion from multiple myeloma cells, comprising:
- providing a p38 MAP kinase inhibitor and a proteasome inhibitor a subject suffering from MM, wherein the secretion rate of a MM-related cytokine is reduced as compared to the secretion rate of a MM-related cytokine of untreated MM cells.
A method of overcoming drug resistance in MM tumor cells comprising:
- identifying a drug resistant MM tumor cell;
- and
- providing a p38 MAPK inhibitor and a chemotherapeutic agent effective in inhibiting MM cell growth, whereby a synergistic interaction of the p38 MAPK inhibitor and the chemotherapeutic agent overcome the drug resistance of the MM tumor cells.
Dependencies are inferred from the claim text.